Valenta Danielle

Yang Zhiyong, Quigley Harry A, Pease Mary E, Yang Yanqin, Qian Jiang, Valenta Danielle et al.

This study identified gene expression changes unique to experimental glaucoma, highlighting neuroinflammation and TNF-alpha pathways as key drivers of both protective and damaging processes in retinal ganglion cells.

Blair Michael, Pease Mary Ellen, Hammond John, Valenta Danielle, Kielczewski Jennifer, Levkovitch-Verbin Hana et al.

Glatiramer acetate was studied for retinal ganglion cell protection after optic nerve injury. It showed no neuroprotective effect; thus, it's not a viable treatment for glaucoma-related nerve damage.

Martin Keith R G, Quigley Harry A, Zack Donald J, Levkovitch-Verbin Hana, Kielczewski Jennifer, Valenta Danielle et al.

Gene therapy delivering BDNF via AAV protected retinal ganglion cells in a rat glaucoma model, suggesting neurotrophic therapy could complement IOP lowering in human glaucoma treatment.

Levkovitch-Verbin Hana, Martin Keith R G, Quigley Harry A, Baumrind Lisa A, Pease Mary Ellen, Valenta Danielle

Rat vitreous protein increased in experimental glaucoma and optic nerve injury, but amino acid levels, including glutamate, remained largely unchanged, suggesting protein leakage rather than amino acid dysregulation.

Martin Keith R G, Levkovitch-Verbin Hana, Valenta Danielle, Baumrind Lisa, Pease Mary Ellen, Quigley Harry A

Experimental glaucoma in rats reduced retinal glutamate transporters (GLT-1, GLAST), unlike optic nerve transection. This suggests impaired glutamate buffering may worsen glaucoma-related retinal ganglion cell damage.

Levkovitch-Verbin Hana, Quigley Harry A, Martin Keith R G, Valenta Danielle, Baumrind Lisa A, Pease Mary Ellen

Researchers developed a rat glaucoma model using translimbal laser to the trabecular meshwork. This method effectively elevated IOP, causing significant retinal ganglion cell loss, providing a useful experimental tool for glaucoma research.